Safety and effectiveness of oral blonanserin for schizophrenia in adolescents in China: Data from a 12-week post-marketing surveillance

• Yun Yu ^[2] ; Xijin Wang ^[3] ; Ruiling Zhang ^[4] ; Keqing Li ^[5] ; Gang Wang ^[6] ; Jindong Chen ^[1] ; Meijuan Sun ^[7] ; Zhiyuan Xun ^[8] ; Xiaodong Yang ^[9] ; Guijun Zhao ^[10] ; Haiyun Li ^[11] ; Xuejun Liu ^[12]
  1. [1] Second Xiangya Hospital of Central South University

     Second Xiangya Hospital of Central South University

     China

     
  2. [2] Department of Psychiatry, Brain Hospital of Hunan Province, Changsha 410007, Hunan, China
  3. [3] Department of Psychiatry, the First Psychiatric Hospital of Harbin, Harbin 150010, Heilongjiang, China
  4. [4] Department of Psychiatry, Henan Mental Hospital, Xinxiang 453002, Henan, China
  5. [5] Department of Psychiatry, Hebei Provincial Mental Health Center, Baoding 071000, Hebei, China
  6. [6] The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100088, China
  7. [7] Department of Pharmacy, Daqing Third Hospital, Daqing 163712, Heilongjiang, China
  8. [8] Department of Psychiatry, Tianjin Anding Hospital, Tianjin 300222, Tianjin, China
  9. [9] Department of Psychiatry, Shandong Mental Health center, Jinan 250014, Shandong, China
  10. [10] Department of Psychiatry, Guangyuan Mental Health Center, Guangyuan 628001, Sichuan, China
  11. [11] Medical Affairs, Sumitomo Pharma (Suzhou) Co. Ltd. Shanghai 200025, Shanghai, China
  12. [12] a Department of Psychiatry, Brain Hospital of Hunan Province, Changsha 410007, Hunan, China

  Mostrar afiliaciones +
• Localización: European journal of psychiatry, ISSN 0213-6163, Vol. 37, Nº 4, 2023
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Background and objectives: Blonanserin is a second-generation antipsychotic (SGA)for the treatment of schizophrenia and has been approved for use in Japan, South Korea and China. This analysis aimed to evaluate the effectiveness and safety of blonanserin in Chinese adolescent patients, using data from a post-marketing surveillance of blonanserin started in September 2018.

    Methods: A 12-week, prospective, multi-center, open-label post-marketing surveillance was conducted. Patients in this analysis were stratified by age.

    Results: 78 patients with schizophrenia aged < 18 years were included. The incidence of adverse drug reactions in adolescent patients was 33.3% significantly higher than patients over 40 years old. After 12-week treatment, 8.1% of adolescent patients had a weight gain ≥ 7%, and it was not significantly different from other age groups. Mean Brief Psychiatric Rating Scale (BPRS) total score was significantly reduced at week 12, and the decline of anergia score and thought disturbance score of adolescent patients was significantly greater than in adults.

    Conclusions: Blonanserin was well tolerated and effective in the treatment of schizophrenia in Chinese adolescent patients in real-world clinical practice. Blonanserin might be a reasonable choice for the treatment of schizophrenia in adolescent patients.

    © 2023 Sociedad Española de Psiquiatría y Salud Mental. Published by Elsevier España, S.L.U. All rights reserved.